Hyperthermia Treatment for Cancer Comprehensive Study by Application (Head and neck, Brain, Lung, Endometrial, Breast, Bladder, Others), Technology (Ultrasound, Electromagnetic, Microwaves, Infrared), Treatment Type (Local, Regional, Whole-Body), End-Use (Hospitals, Clinics, Research Institutes, Cancer Centers, Others) Players and Region - Global Market Outlook to 2030

Hyperthermia Treatment for Cancer Market by XX Submarkets | Forecast Years 2024-2030  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hyperthermia Treatment for Cancer
Hyperthermia treatment is a non-invasive method of raising the temperature of the tumor to stimulate blood flow, surge oxygenation and reduce tumor cells more sensitive to radiation. By adding hyperthermia to radiotherapy, radiation oncologists can increase tumor control while reducing damage to healthy tissue. Hyperthermia make some cancer cells more sensitive to radiation or damage other cancer cells that cannot be damage by the radiation. When hyperthermia and radiotherapy are combined, they're often given within an hour of every other. Hyperthermia also can enhance the consequences of certain anticancer drugs. According to WHO cancer is a leading cause of death worldwide, accounting for ~9.6 million deaths in 2018.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Hyperthermia Treatment for Cancer market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Celsius42+ GmbH (Germany), Pyrexar Medical Inc. (United States), Oncothermia (United States), Hydrosun GmbH (Germany), Yamamoto Vinita Co., Ltd (Japan), Andromedic Srl (Italy) and Haifu Medical Technology Co. Ltd (China) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Hyperthermia Treatment for Cancer market by , Application (Head and neck, Brain, Lung, Endometrial, Breast, Bladder and Others) and Region.



On the basis of geography, the market of Hyperthermia Treatment for Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Technology, the sub-segment i.e. Ultrasound will boost the Hyperthermia Treatment for Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Local will boost the Hyperthermia Treatment for Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-Use, the sub-segment i.e. Hospitals will boost the Hyperthermia Treatment for Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased R&D Expenditure of Pharmaceutical Companies and Growing Awareness Regarding the Therapeutic Effect of Hyperthermia

Market Growth Drivers:
The increasing adoption of advanced therapy techniques and Increasing Prevalence of Lungs Cancer

Challenges:
With Current Methods It Is Sometimes Hard To Keep the Body within an Exact Temperature Range

Restraints:
High Cost Associated with Treatment and Side Effects of Hyperthermia Treatment

Opportunities:
Increased Investments from Governments and Private Organizations for Research & Development




Key Target Audience
Hyperthermia Treatment Providers, Healthcare Industry, Research Institutes, Government Agencies, Medical Research Laboratories and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Head and neck
  • Brain
  • Lung
  • Endometrial
  • Breast
  • Bladder
  • Others
By Technology
  • Ultrasound
  • Electromagnetic
  • Microwaves
  • Infrared

By Treatment Type
  • Local
  • Regional
  • Whole-Body

By End-Use
  • Hospitals
  • Clinics
  • Research Institutes
  • Cancer Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The increasing adoption of advanced therapy techniques
      • 3.2.2. Increasing Prevalence of Lungs Cancer
    • 3.3. Market Challenges
      • 3.3.1. With Current Methods It Is Sometimes Hard To Keep the Body within an Exact Temperature Range
    • 3.4. Market Trends
      • 3.4.1. Increased R&D Expenditure of Pharmaceutical Companies
      • 3.4.2. Growing Awareness Regarding the Therapeutic Effect of Hyperthermia
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hyperthermia Treatment for Cancer, by Application, Technology, Treatment Type, End-Use and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hyperthermia Treatment for Cancer (Value)
      • 5.2.1. Global Hyperthermia Treatment for Cancer by: Application (Value)
        • 5.2.1.1. Head and neck
        • 5.2.1.2. Brain
        • 5.2.1.3. Lung
        • 5.2.1.4. Endometrial
        • 5.2.1.5. Breast
        • 5.2.1.6. Bladder
        • 5.2.1.7. Others
      • 5.2.2. Global Hyperthermia Treatment for Cancer by: Technology (Value)
        • 5.2.2.1. Ultrasound
        • 5.2.2.2. Electromagnetic
        • 5.2.2.3. Microwaves
        • 5.2.2.4. Infrared
      • 5.2.3. Global Hyperthermia Treatment for Cancer by: Treatment Type (Value)
        • 5.2.3.1. Local
        • 5.2.3.2. Regional
        • 5.2.3.3. Whole-Body
      • 5.2.4. Global Hyperthermia Treatment for Cancer by: End-Use (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
        • 5.2.4.3. Research Institutes
        • 5.2.4.4. Cancer Centers
        • 5.2.4.5. Others
      • 5.2.5. Global Hyperthermia Treatment for Cancer Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Hyperthermia Treatment for Cancer (Price)
  • 6. Hyperthermia Treatment for Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Celsius42+ GmbH (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pyrexar Medical Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Oncothermia (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hydrosun GmbH (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Yamamoto Vinita Co., Ltd (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Andromedic Srl (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Haifu Medical Technology Co. Ltd (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Hyperthermia Treatment for Cancer Sale, by Application, Technology, Treatment Type, End-Use and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hyperthermia Treatment for Cancer (Value)
      • 7.2.1. Global Hyperthermia Treatment for Cancer by: Application (Value)
        • 7.2.1.1. Head and neck
        • 7.2.1.2. Brain
        • 7.2.1.3. Lung
        • 7.2.1.4. Endometrial
        • 7.2.1.5. Breast
        • 7.2.1.6. Bladder
        • 7.2.1.7. Others
      • 7.2.2. Global Hyperthermia Treatment for Cancer by: Technology (Value)
        • 7.2.2.1. Ultrasound
        • 7.2.2.2. Electromagnetic
        • 7.2.2.3. Microwaves
        • 7.2.2.4. Infrared
      • 7.2.3. Global Hyperthermia Treatment for Cancer by: Treatment Type (Value)
        • 7.2.3.1. Local
        • 7.2.3.2. Regional
        • 7.2.3.3. Whole-Body
      • 7.2.4. Global Hyperthermia Treatment for Cancer by: End-Use (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
        • 7.2.4.3. Research Institutes
        • 7.2.4.4. Cancer Centers
        • 7.2.4.5. Others
      • 7.2.5. Global Hyperthermia Treatment for Cancer Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Hyperthermia Treatment for Cancer (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hyperthermia Treatment for Cancer: by Application(USD Million)
  • Table 2. Hyperthermia Treatment for Cancer Head and neck , by Region USD Million (2018-2023)
  • Table 3. Hyperthermia Treatment for Cancer Brain , by Region USD Million (2018-2023)
  • Table 4. Hyperthermia Treatment for Cancer Lung , by Region USD Million (2018-2023)
  • Table 5. Hyperthermia Treatment for Cancer Endometrial , by Region USD Million (2018-2023)
  • Table 6. Hyperthermia Treatment for Cancer Breast , by Region USD Million (2018-2023)
  • Table 7. Hyperthermia Treatment for Cancer Bladder , by Region USD Million (2018-2023)
  • Table 8. Hyperthermia Treatment for Cancer Others , by Region USD Million (2018-2023)
  • Table 9. Hyperthermia Treatment for Cancer: by Technology(USD Million)
  • Table 10. Hyperthermia Treatment for Cancer Ultrasound , by Region USD Million (2018-2023)
  • Table 11. Hyperthermia Treatment for Cancer Electromagnetic , by Region USD Million (2018-2023)
  • Table 12. Hyperthermia Treatment for Cancer Microwaves , by Region USD Million (2018-2023)
  • Table 13. Hyperthermia Treatment for Cancer Infrared , by Region USD Million (2018-2023)
  • Table 14. Hyperthermia Treatment for Cancer: by Treatment Type(USD Million)
  • Table 15. Hyperthermia Treatment for Cancer Local , by Region USD Million (2018-2023)
  • Table 16. Hyperthermia Treatment for Cancer Regional , by Region USD Million (2018-2023)
  • Table 17. Hyperthermia Treatment for Cancer Whole-Body , by Region USD Million (2018-2023)
  • Table 18. Hyperthermia Treatment for Cancer: by End-Use(USD Million)
  • Table 19. Hyperthermia Treatment for Cancer Hospitals , by Region USD Million (2018-2023)
  • Table 20. Hyperthermia Treatment for Cancer Clinics , by Region USD Million (2018-2023)
  • Table 21. Hyperthermia Treatment for Cancer Research Institutes , by Region USD Million (2018-2023)
  • Table 22. Hyperthermia Treatment for Cancer Cancer Centers , by Region USD Million (2018-2023)
  • Table 23. Hyperthermia Treatment for Cancer Others , by Region USD Million (2018-2023)
  • Table 24. South America Hyperthermia Treatment for Cancer, by Country USD Million (2018-2023)
  • Table 25. South America Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 26. South America Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 27. South America Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 28. South America Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 29. Brazil Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 30. Brazil Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 31. Brazil Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 32. Brazil Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 33. Argentina Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 34. Argentina Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 35. Argentina Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 36. Argentina Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 37. Rest of South America Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 38. Rest of South America Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 39. Rest of South America Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 40. Rest of South America Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 41. Asia Pacific Hyperthermia Treatment for Cancer, by Country USD Million (2018-2023)
  • Table 42. Asia Pacific Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 43. Asia Pacific Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 44. Asia Pacific Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 45. Asia Pacific Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 46. China Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 47. China Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 48. China Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 49. China Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 50. Japan Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 51. Japan Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 52. Japan Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 53. Japan Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 54. India Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 55. India Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 56. India Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 57. India Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 58. South Korea Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 59. South Korea Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 60. South Korea Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 61. South Korea Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 62. Taiwan Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 63. Taiwan Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 64. Taiwan Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 65. Taiwan Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 66. Australia Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 67. Australia Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 68. Australia Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 69. Australia Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 73. Rest of Asia-Pacific Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 74. Europe Hyperthermia Treatment for Cancer, by Country USD Million (2018-2023)
  • Table 75. Europe Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 76. Europe Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 77. Europe Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 78. Europe Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 79. Germany Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 80. Germany Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 81. Germany Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 82. Germany Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 83. France Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 84. France Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 85. France Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 86. France Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 87. Italy Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 88. Italy Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 89. Italy Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 90. Italy Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 91. United Kingdom Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 92. United Kingdom Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 93. United Kingdom Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 94. United Kingdom Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 95. Netherlands Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 96. Netherlands Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 97. Netherlands Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 98. Netherlands Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 99. Rest of Europe Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 100. Rest of Europe Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 101. Rest of Europe Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 102. Rest of Europe Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 103. MEA Hyperthermia Treatment for Cancer, by Country USD Million (2018-2023)
  • Table 104. MEA Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 105. MEA Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 106. MEA Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 107. MEA Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 108. Middle East Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 109. Middle East Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 110. Middle East Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 111. Middle East Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 112. Africa Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 113. Africa Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 114. Africa Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 115. Africa Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 116. North America Hyperthermia Treatment for Cancer, by Country USD Million (2018-2023)
  • Table 117. North America Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 118. North America Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 119. North America Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 120. North America Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 121. United States Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 122. United States Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 123. United States Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 124. United States Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 125. Canada Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 126. Canada Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 127. Canada Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 128. Canada Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 129. Mexico Hyperthermia Treatment for Cancer, by Application USD Million (2018-2023)
  • Table 130. Mexico Hyperthermia Treatment for Cancer, by Technology USD Million (2018-2023)
  • Table 131. Mexico Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2018-2023)
  • Table 132. Mexico Hyperthermia Treatment for Cancer, by End-Use USD Million (2018-2023)
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Hyperthermia Treatment for Cancer: by Application(USD Million)
  • Table 141. Hyperthermia Treatment for Cancer Head and neck , by Region USD Million (2025-2030)
  • Table 142. Hyperthermia Treatment for Cancer Brain , by Region USD Million (2025-2030)
  • Table 143. Hyperthermia Treatment for Cancer Lung , by Region USD Million (2025-2030)
  • Table 144. Hyperthermia Treatment for Cancer Endometrial , by Region USD Million (2025-2030)
  • Table 145. Hyperthermia Treatment for Cancer Breast , by Region USD Million (2025-2030)
  • Table 146. Hyperthermia Treatment for Cancer Bladder , by Region USD Million (2025-2030)
  • Table 147. Hyperthermia Treatment for Cancer Others , by Region USD Million (2025-2030)
  • Table 148. Hyperthermia Treatment for Cancer: by Technology(USD Million)
  • Table 149. Hyperthermia Treatment for Cancer Ultrasound , by Region USD Million (2025-2030)
  • Table 150. Hyperthermia Treatment for Cancer Electromagnetic , by Region USD Million (2025-2030)
  • Table 151. Hyperthermia Treatment for Cancer Microwaves , by Region USD Million (2025-2030)
  • Table 152. Hyperthermia Treatment for Cancer Infrared , by Region USD Million (2025-2030)
  • Table 153. Hyperthermia Treatment for Cancer: by Treatment Type(USD Million)
  • Table 154. Hyperthermia Treatment for Cancer Local , by Region USD Million (2025-2030)
  • Table 155. Hyperthermia Treatment for Cancer Regional , by Region USD Million (2025-2030)
  • Table 156. Hyperthermia Treatment for Cancer Whole-Body , by Region USD Million (2025-2030)
  • Table 157. Hyperthermia Treatment for Cancer: by End-Use(USD Million)
  • Table 158. Hyperthermia Treatment for Cancer Hospitals , by Region USD Million (2025-2030)
  • Table 159. Hyperthermia Treatment for Cancer Clinics , by Region USD Million (2025-2030)
  • Table 160. Hyperthermia Treatment for Cancer Research Institutes , by Region USD Million (2025-2030)
  • Table 161. Hyperthermia Treatment for Cancer Cancer Centers , by Region USD Million (2025-2030)
  • Table 162. Hyperthermia Treatment for Cancer Others , by Region USD Million (2025-2030)
  • Table 163. South America Hyperthermia Treatment for Cancer, by Country USD Million (2025-2030)
  • Table 164. South America Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 165. South America Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 166. South America Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 167. South America Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 168. Brazil Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 169. Brazil Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 170. Brazil Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 171. Brazil Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 172. Argentina Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 173. Argentina Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 174. Argentina Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 175. Argentina Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 176. Rest of South America Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 177. Rest of South America Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 178. Rest of South America Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 179. Rest of South America Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 180. Asia Pacific Hyperthermia Treatment for Cancer, by Country USD Million (2025-2030)
  • Table 181. Asia Pacific Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 182. Asia Pacific Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 183. Asia Pacific Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 184. Asia Pacific Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 185. China Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 186. China Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 187. China Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 188. China Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 189. Japan Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 190. Japan Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 191. Japan Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 192. Japan Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 193. India Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 194. India Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 195. India Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 196. India Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 197. South Korea Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 198. South Korea Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 199. South Korea Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 200. South Korea Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 201. Taiwan Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 202. Taiwan Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 203. Taiwan Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 204. Taiwan Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 205. Australia Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 206. Australia Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 207. Australia Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 208. Australia Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 209. Rest of Asia-Pacific Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 210. Rest of Asia-Pacific Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 211. Rest of Asia-Pacific Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 212. Rest of Asia-Pacific Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 213. Europe Hyperthermia Treatment for Cancer, by Country USD Million (2025-2030)
  • Table 214. Europe Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 215. Europe Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 216. Europe Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 217. Europe Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 218. Germany Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 219. Germany Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 220. Germany Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 221. Germany Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 222. France Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 223. France Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 224. France Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 225. France Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 226. Italy Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 227. Italy Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 228. Italy Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 229. Italy Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 230. United Kingdom Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 231. United Kingdom Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 232. United Kingdom Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 233. United Kingdom Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 234. Netherlands Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 235. Netherlands Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 236. Netherlands Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 237. Netherlands Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 238. Rest of Europe Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 239. Rest of Europe Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 240. Rest of Europe Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 241. Rest of Europe Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 242. MEA Hyperthermia Treatment for Cancer, by Country USD Million (2025-2030)
  • Table 243. MEA Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 244. MEA Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 245. MEA Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 246. MEA Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 247. Middle East Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 248. Middle East Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 249. Middle East Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 250. Middle East Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 251. Africa Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 252. Africa Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 253. Africa Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 254. Africa Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 255. North America Hyperthermia Treatment for Cancer, by Country USD Million (2025-2030)
  • Table 256. North America Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 257. North America Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 258. North America Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 259. North America Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 260. United States Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 261. United States Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 262. United States Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 263. United States Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 264. Canada Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 265. Canada Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 266. Canada Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 267. Canada Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 268. Mexico Hyperthermia Treatment for Cancer, by Application USD Million (2025-2030)
  • Table 269. Mexico Hyperthermia Treatment for Cancer, by Technology USD Million (2025-2030)
  • Table 270. Mexico Hyperthermia Treatment for Cancer, by Treatment Type USD Million (2025-2030)
  • Table 271. Mexico Hyperthermia Treatment for Cancer, by End-Use USD Million (2025-2030)
  • Table 272. Research Programs/Design for This Report
  • Table 273. Key Data Information from Secondary Sources
  • Table 274. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hyperthermia Treatment for Cancer: by Application USD Million (2018-2023)
  • Figure 5. Global Hyperthermia Treatment for Cancer: by Technology USD Million (2018-2023)
  • Figure 6. Global Hyperthermia Treatment for Cancer: by Treatment Type USD Million (2018-2023)
  • Figure 7. Global Hyperthermia Treatment for Cancer: by End-Use USD Million (2018-2023)
  • Figure 8. South America Hyperthermia Treatment for Cancer Share (%), by Country
  • Figure 9. Asia Pacific Hyperthermia Treatment for Cancer Share (%), by Country
  • Figure 10. Europe Hyperthermia Treatment for Cancer Share (%), by Country
  • Figure 11. MEA Hyperthermia Treatment for Cancer Share (%), by Country
  • Figure 12. North America Hyperthermia Treatment for Cancer Share (%), by Country
  • Figure 13. Global Hyperthermia Treatment for Cancer share by Players 2023 (%)
  • Figure 14. Global Hyperthermia Treatment for Cancer share by Players (Top 3) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Celsius42+ GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 17. Celsius42+ GmbH (Germany) Revenue: by Geography 2023
  • Figure 18. Pyrexar Medical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pyrexar Medical Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Oncothermia (United States) Revenue, Net Income and Gross profit
  • Figure 21. Oncothermia (United States) Revenue: by Geography 2023
  • Figure 22. Hydrosun GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Hydrosun GmbH (Germany) Revenue: by Geography 2023
  • Figure 24. Yamamoto Vinita Co., Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Yamamoto Vinita Co., Ltd (Japan) Revenue: by Geography 2023
  • Figure 26. Andromedic Srl (Italy) Revenue, Net Income and Gross profit
  • Figure 27. Andromedic Srl (Italy) Revenue: by Geography 2023
  • Figure 28. Haifu Medical Technology Co. Ltd (China) Revenue, Net Income and Gross profit
  • Figure 29. Haifu Medical Technology Co. Ltd (China) Revenue: by Geography 2023
  • Figure 30. Global Hyperthermia Treatment for Cancer: by Application USD Million (2025-2030)
  • Figure 31. Global Hyperthermia Treatment for Cancer: by Technology USD Million (2025-2030)
  • Figure 32. Global Hyperthermia Treatment for Cancer: by Treatment Type USD Million (2025-2030)
  • Figure 33. Global Hyperthermia Treatment for Cancer: by End-Use USD Million (2025-2030)
  • Figure 34. South America Hyperthermia Treatment for Cancer Share (%), by Country
  • Figure 35. Asia Pacific Hyperthermia Treatment for Cancer Share (%), by Country
  • Figure 36. Europe Hyperthermia Treatment for Cancer Share (%), by Country
  • Figure 37. MEA Hyperthermia Treatment for Cancer Share (%), by Country
  • Figure 38. North America Hyperthermia Treatment for Cancer Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Celsius42+ GmbH (Germany)
  • Pyrexar Medical Inc. (United States)
  • Oncothermia (United States)
  • Hydrosun GmbH (Germany)
  • Yamamoto Vinita Co., Ltd (Japan)
  • Andromedic Srl (Italy)
  • Haifu Medical Technology Co. Ltd (China)
Select User Access Type

Key Highlights of Report


Mar 2024 224 Pages 56 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Celsius42+ GmbH (Germany), Pyrexar Medical Inc. (United States), Oncothermia (United States), Hydrosun GmbH (Germany), Yamamoto Vinita Co., Ltd (Japan), Andromedic Srl (Italy) and Haifu Medical Technology Co. Ltd (China) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased R&D Expenditure of Pharmaceutical Companies " is seen as one of major influencing trends for Hyperthermia Treatment for Cancer Market during projected period 2023-2030.
The Hyperthermia Treatment for Cancer market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hyperthermia Treatment for Cancer Report?